ArticleScientific reports2021
Evaluation of Acanthamoeba keratitis cases in a tertiary medical care centre over 21 years.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Benzophenone Derivatives as a New Class of Anti-Infectives Against Acanthamoeba spp.Archiv der Pharmazie · 2026Article
- Dysregulated Intraocular Pressure in Acanthamoeba Keratitis: Clinical Associations, Therapy, and Prognosis.Microorganisms · 2026Article
- Infectious Keratitis: A Retrospective Analysis of a Tertiary Care Center.Journal of clinical medicine · 2026Article
- Acanthamoeba Keratitis: 34-Year Epidemiological Profile.Antibiotics (Basel, Switzerland) · 2026Article
- In vitro evaluation of 4,4'-trimethylenedipyridinium and 4,4'-trimethylenedipiperidinium-based polycationic polymers against Acanthamoeba hatchetti.Parasitology research · 2025Article
- Complicated Diagnosis and Treatment of Rare PainlessJournal of clinical medicine · 2025Article
- Acanthamoeba Keratitis Management and Prognostic Factors: A Systematic Review.Journal of clinical medicine · 2025Review
- The pathogenesis, risk factors, diagnosis and treatment of Acanthamoeba keratitis.Frontiers in medicine · 2025Review
- Review
- Staurosporine as a Potential Treatment forMarine drugs · 2024Article
- Rethinking Keratoplasty for Patients with Acanthamoeba Keratitis: Early "Low Load Keratoplasty" in Contrast to Late Optical and Therapeutic Keratoplasty.Microorganisms · 2024Article
- Characterization of novel extracellular proteases produced by Acanthamoeba castellanii after contact with human corneal epithelial cells and their relevance to pathogenesis.Parasites & vectors · 2024Article
- Acanthamoeba Keratitis in China: Genotypic and Clinical Correlations.Translational vision science & technology · 2024Article
- The role of naturally acquired intracellular Pseudomonas aeruginosa in the development of Acanthamoeba keratitis in an animal model.PLoS neglected tropical diseases · 2024Article
- Differentiation of acanthamoeba keratitis from other non-acanthamoeba keratitis: Risk factors and clinical features.PloS one · 2024Article
- Impact of implementation of polymerase chain reaction on diagnosis, treatment, and clinical course of Acanthamoeba keratitis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- Impact of First Healthcare Provider onClinical ophthalmology (Auckland, N.Z.) · 2023Article
- The Anti-Amoebic Activity of a Peptidomimetic againstMicroorganisms · 2022Article
- The Activity of Polyhomoarginine againstBiology · 2022Article
- Assessment of genotypes, endosymbionts and clinical characteristics of Acanthamoeba recovered from ocular infection.BMC infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To report on Acanthamoeba keratitis cases in a tertiary university eye-hospital in Graz, Austria, over a 21-year period. Retrospective study. Parameters included demographics, diagnostics, clinical courses, medical therapies, surgical interventions, secondary complications, and best spectacle-corrected visual acuity (BSCVA). Patient records for 44 eyes of 42 patients were analysed; 2 bilateral infections. Mean age at presentation was 31 ± 13 (16-65) years; contact lenses were used in 41 of 44 eyes (93.2%). Symptoms at initial presentation were mainly pain (41/43, 95.3%) and photophobia (16/43, 37.2%). Most frequent morphological findings were stromal infiltrates (30/44, 68.2%). Diagnosis was mainly confirmed by smears (40/42, 95.2%) and polymerase chain reaction (8/42, 19%). Antiamoebic treatment comprised biguanides and diamidines. Penetrating keratoplasty was performed in 10/44 (22.7%) eyes. Median time from symptom onset to initial visit was 2 (0-26) weeks; median follow-up was 30 (2-1008) weeks. BSCVA improved in 23/36 (63.9%) eyes, remained unchanged in 6/36 (16.7%) eyes and deteriorated in 7/36 (19.4%) eyes. Acanthamoeba keratitis predominantly occurs in young contact lens wearers. Diagnosis should be considered in patients with pain and stromal infiltrates. In the majority of cases, BSCVA can be improved. Early diagnosis and adequate treatment should be implemented to prevent complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.